Table 2.
Characteristics of 379 medulloblastoma participants by amifostine treatment status
| Variable | Amifostine = No (n = 51) | Amifostine = Yes (n = 328) |
|---|---|---|
| Age at study enrollment (years) [median (min, max]) | 7.3 (3.2, 17.2) | 8.3 (3.1, 21.6) |
| Sex | ||
| Female (%) | 18 (35.3%) | 118 (36.0%) |
| Male (%) | 33 (64.7%) | 210 (64.0%) |
| Race | ||
| Non-white (%) | 13 (25.5%) | 73 (22.3%) |
| White | 38 (74.5%) | 255 (77.7%) |
| Institution | ||
| St. Jude | 27 (52.9%) | 165 (50.3%) |
| Collaborative institution | 24 (47.1%) | 163 (49.7%) |
| Cumulative cisplatin dosage (mg/m2) [median (min, max)] | 301.0 (76.8, 329.4) | 299.8 (74.5, 312.2) |
| Time from treatment initiation to latest audiogram (months) [median (min, max]) | 18.9 (6.3, 24.3) | 19.5 (5.6, 24.5) |
| Study protocol | ||
| SJMB03 | 3 (5.9%) | 263 (80.2%) |
| SJMB96 | 48 (94.1%) | 65 (19.8%) |
| Disease risk category | ||
| Average | 34 (66.7%) | 229 (69.8%) |
| High | 17 (33.3%) | 99 (30.2%) |
| Chang Grade | ||
| 0 | 9 (17.7%) | 118 (36.0%) |
| 1a | 9 (17.7%) | 60 (18.3%) |
| 1b | 4 (7.8%) | 24 (7.3%) |
| 2a | 2 (3.9%) | 22 (6.7%) |
| 2b | 5 (9.8%) | 19 (5.8%) |
| 3 | 18 (35.3%) | 77 (23.5%) |
| 4 | 4 (7.8%) | 8 (2.4%) |
Abbreviation: St Jude, St. Jude Children's Research Hospital.